Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643088 | 0.90 | PTGDR2 (0.44) | LMNASMN1; SMN2PTGDR2TBXA2RPTGDR | |
| SCHEMBL13760999 | 0.90 | PTGDR2 (0.46) | LMNASMN1; SMN2PTGDR2TBXA2RPTGDR | |
| SCHEMBL1644488 | 0.90 | PTGDR2 (0.46) | LMNASMN1; SMN2PTGDR2TBXA2RPTGDR | |
| SCHEMBL148769 | 0.84 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL1643183 | 0.83 | KDM4E (0.44) | LMNASMN1; SMN2PTGDR2TBXA2RPTGDR | |
| SCHEMBL1643585 | 0.82 | MEN1 (0.47) | LMNASMN1; SMN2PTGDR2KMT2AKDM4E | |
| SCHEMBL13761111 | 0.81 | PTGDR2 (0.43) | LMNASMN1; SMN2PTGDR2TBXA2RPTGDR | |
| SCHEMBL1644127 | 0.81 | DRD2 (0.45) | PTGDR2TBXA2RPTGDRFFAR1FFAR2 | |
| SCHEMBL1945418 | 0.80 | PTGDR2 (0.47) | LMNASMN1; SMN2PTGDR2TBXA2RPTGDR | |
| SCHEMBL1643054 | 0.80 | PTGDR2 (0.41) | LMNASMN1; SMN2PTGDR2TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009102893-A2 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER1 | LMNA 2386/4885SMN1; SMN2 4772/4885PTGDR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.